Limits...
Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission.

Hisamatsu T, Ono N, Imaizumi A, Mori M, Suzuki H, Uo M, Hashimoto M, Naganuma M, Matsuoka K, Mizuno S, Kitazume MT, Yajima T, Ogata H, Iwao Y, Hibi T, Kanai T - PLoS ONE (2015)

Bottom Line: Ulcerative colitis (UC) is characterized by chronic intestinal inflammation.The age- and gender-adjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (log-rank), p for trend = 0.0005).Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan; Division of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

ABSTRACT
Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age- and gender-adjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (log-rank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

No MeSH data available.


Related in: MedlinePlus

Kaplan—Meier analysis of whole patients who have successfully followed up.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4608807&req=5

pone.0140716.g002: Kaplan—Meier analysis of whole patients who have successfully followed up.

Mentions: We obtained informed consent from 467 UC patients in remission. Ninety-eight patients were withdrawn before baseline (10 declined to participate, 12 failed to attended after agreeing to participate, and 76 did not meet the study criteria). A total of 369 UC patients in remission were enrolled and we measured fasted PFAA concentrations. During 1 year follow-up, 14 patients were withdrawn. Finally, 355 patients were successfully followed up and analyzed. Within 1 year after enrollment, 82 patients had relapsed (relapse rate 23%, Fig 1). Kaplan—Meier analysis is shown in Fig 2.


Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission.

Hisamatsu T, Ono N, Imaizumi A, Mori M, Suzuki H, Uo M, Hashimoto M, Naganuma M, Matsuoka K, Mizuno S, Kitazume MT, Yajima T, Ogata H, Iwao Y, Hibi T, Kanai T - PLoS ONE (2015)

Kaplan—Meier analysis of whole patients who have successfully followed up.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4608807&req=5

pone.0140716.g002: Kaplan—Meier analysis of whole patients who have successfully followed up.
Mentions: We obtained informed consent from 467 UC patients in remission. Ninety-eight patients were withdrawn before baseline (10 declined to participate, 12 failed to attended after agreeing to participate, and 76 did not meet the study criteria). A total of 369 UC patients in remission were enrolled and we measured fasted PFAA concentrations. During 1 year follow-up, 14 patients were withdrawn. Finally, 355 patients were successfully followed up and analyzed. Within 1 year after enrollment, 82 patients had relapsed (relapse rate 23%, Fig 1). Kaplan—Meier analysis is shown in Fig 2.

Bottom Line: Ulcerative colitis (UC) is characterized by chronic intestinal inflammation.The age- and gender-adjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (log-rank), p for trend = 0.0005).Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan; Division of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan.

ABSTRACT
Ulcerative colitis (UC) is characterized by chronic intestinal inflammation. Patients with UC have repeated remission and relapse. Clinical biomarkers that can predict relapse in UC patients in remission have not been identified. To facilitate the prediction of relapse of UC, we investigated the potential of novel multivariate indexes using statistical modeling of plasma free amino acid (PFAA) concentrations. We measured fasting PFAA concentrations in 369 UC patients in clinical remission, and 355 were observed prospectively for up to 1 year. Relapse rate within 1 year was 23% (82 of 355 patients). The age- and gender-adjusted hazard ratio for the lowest quartile compared with the highest quartile of plasma histidine concentration was 2.55 (95% confidence interval: 1.41-4.62; p = 0.0020 (log-rank), p for trend = 0.0005). We demonstrated that plasma amino acid profiles in UC patients in clinical remission can predict the risk of relapse within 1 year. Decreased histidine level in PFAAs was associated with increased risk of relapse. Metabolomics could be promising for the establishment of a non-invasive predictive marker in inflammatory bowel disease.

No MeSH data available.


Related in: MedlinePlus